.jpg?format=webp&width=780)
A study highlights potential misinterpretations regarding therapy outcomes in chronic myeloid leukemia (CML) patients undergoing tyrosine kinase-inhibitor (TKI)-therapy. The study, involving 821 individuals, suggests a link between the duration of TKI therapy and deep molecular response (DMR) intervals with achieving therapy-free remission (TFR). This analysis underlines the complexity of TFR prediction, emphasizing the need to consider diverse variables carefully.
Like
Save
Share